CV Therapeutics' Ranexa gains US approval for first-line use in angina
This article was originally published in Scrip
Executive Summary
CV Therapeutics'santi-anginal Ranexa (ranolazine extended-release tablets) has received US FDAapproval for a new, first-line indication for the treatment of chronic angina. The revised label also includes additional claims that Ranexa reduces arrhythmias – including ventricular arrhythmias, new atrial fibrillation and bradycardia – and also reduces HbA